Alliance for Pandemic Preparedness

November 23, 2020

Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial

Category:

Topic:

Keywords (Tags):

A novel chimpanzee adenovirus-vectored vaccine, ChAdOx1 nCoV-19, was reported to be safe and well tolerated with reduced reactogenicity in healthy adults aged ≥18 years. A single-blind, randomized phase 2/3 trial in UK (n=552) found that compared to adults who received a control vaccine for meningitis, adults who received ChAdOx1 nCoV-19 developed antibody responses against the SARS-CoV-2 spike protein and sustained them at 28 days after booster vaccination. T-cell immune responses were also induced and peaked at day 14 after vaccination. Results were similar across age groups (18–55 years, 56–69 years, and ≥70 years). As of Oct 26, 2020, 13 serious adverse events occurred during the study period, none of which were considered to be related to either study vaccine. 

Ramasamy et al. (Nov 18, 2020). Safety and Immunogenicity of ChAdOx1 NCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial. Lancet. https://doi.org/10.1016/S0140-6736(20)32466-1